Projects per year
Methods: This was a randomized placebo-controlled double-blind multicenter trial. 80 patients undergoing regular maintenance hemodialysis were recruited from NHS Tayside, NHS Greater Glasgow and Clyde and NHS Ayrshire and Arran in Scotland, UK. Participants were randomly assigned on a 1:1 ratio to 12 months of therapy with allopurinol 300mg or placebo after each dialysis session. The primary outcome was change in LVMI - assessed by cardiac magnetic resonance imaging at baseline and 12 months. Secondary outcomes were change in BP, flow mediated dilation (FMD), augmentation indices (Aix) and pulse wave velocity (PWV).
Results: 53 patients, with a mean age of 58, completed the study and had MRI follow up data for analysis. Allopurinol did not regress LVMI - change in LVMI (g/m2): placebo +3.610.4, allopurinol +1.611 p=0.49. Allopurinol had no demonstrable effect on BP, FMD, Aix or PWV.
Conclusions: Compared with placebo, treatment with allopurinol did not regress LVMI in this trial.
- randomized controlled trial
- left ventricular mass
- magnetic resonance imaging